Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Activist shareholder aims to drive shakeup at immunotherapy firm IMV

By Brian Buntz | June 5, 2021

IMVDr. Michael Gross, an activist shareholder of immunotherapy specialist IMV (NSDQ:IMV), has launched an offensive intended to cause a leadership shakeup at the company.

Gross released a press release on June 1 announcing his plans to oust the company’s board chair Andy Sheldon and the chair of the board’s compensation committee, Julia Gregory.

The director must receive a majority of shareholder votes to retain his role. 

IMV will hold an annual general meeting on June 18. 

On June 4, Gross released a new press release stating that he had the support of approximately 25% of the outstanding common shares of IMV. 

Dr. Michael Gross is an orthopaedic oncologist who became interested in IMV in the course of his practice. “I became interested in IMV’s technology as I lost 50% to 80% of my patients to metastatic disease even after chemotherapy for musculoskeletal cancers,” Gross said. “IMV’s technology arose out of a Laboratory at Dalhousie University. Their Depo technology was found to induce a prolonged survival rate in a mouse model of cancer.”

The research demonstrated that T cells stimulated by an appropriate antigen produced a prolonged effect on tumors. “With the increasing identification of unique tumour markers, there was a huge opportunity to see if chemotherapy-resistant cancers could be treated this way,” Gross said.

Gross said that the company’s most recent share price is leading “many shareholders” to conclude that “the company is not advancing the research quickly enough and that the financing routes taken by management are resulting in significant dilution of the existing share base,” Gross said.

An IMV spokesperson said the company’s management is aware of the concerned shareholder but had no further comment. The company has made recent changes to its board, installing Dr. Michael Kalos and Kyle Kuvalanka. Kalos is an expert in T-cell therapy and immunotherapy, while Kuvalanka is a biopharmaceutical industry veteran. 

The latest press release also noted the shareholder’s frustration with the company’s COVID-19 vaccine program, which it first announced on March 18, 2020. The company is currently undertaking a Phase 1/2 trial for the vaccine. In March, IMV announced it was conducting parallel preclinical research related to new SARS-CoV-2 variants. 

Gross also believes that IMV’s executives are overcompensated in light of the company’s stock performance. 

The company’s CEO Frederic Ors earned $756,300 in total compensation last year, while the company’s CFO, Pierre Labbé, earned $492,300. 

“IMV’s disconnect between pay and performance must be corrected immediately,” he said in a statement. 

In its most recent earnings call, IMV’s CEO said the company continues to progress with its cancer T cell therapy program, including its Maveropepimut-S and dual-targeted T cell therapy DPX-SurMAGE therapies. 


Filed Under: clinical trials, Drug Discovery, Immunology, Oncology
Tagged With: activist shareholder, immunotherapy, IMV, T-cell immunotherapy
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
AP Biosciences charts course for safer CD137 bispecifics with its T-cube platform
Cellares and UW-Madison partner to automate manufacturing for novel solid tumor CAR-T
Why smaller, simpler molecular glues are gaining attention in drug discovery
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE